Literature DB >> 15858042

Role of genes that modulate host immune responses in the immunogenicity and pathogenicity of vaccinia virus.

Shawn S Jackson1, Petr Ilyinskii, Valérie Philippon, Linda Gritz, Alicia Gómez Yafal, Kimberly Zinnack, Kristin R Beaudry, Kelledy H Manson, Michelle A Lifton, Marcelo J Kuroda, Norman L Letvin, Gail P Mazzara, Dennis L Panicali.   

Abstract

Poxvirus vaccine vectors, although capable of eliciting potent immune responses, pose serious health risks in immunosuppressed individuals. We therefore constructed five novel recombinant vaccinia virus vectors which contained overlapping deletions of coding regions for the B5R, B8R, B12R, B13R, B14R, B16R, B18R, and B19R immunomodulatory gene products and assessed them for both immunogenicity and pathogenicity. All five of these novel vectors elicited both cellular and humoral immunity to the inserted HIV-BH10 env comparable to that induced by the parental Wyeth strain vaccinia virus. However, deletion of these immunomodulatory genes did not increase the immunogenicity of these vectors compared with the parental vaccinia virus. Furthermore, four of these vectors were slightly less virulent and one was slightly more virulent than the Wyeth strain virus in neonatal mice. Attenuated poxviruses have potential use as safer alternatives to current replication-competent vaccinia virus. Improved vaccinia virus vectors can be generated by deleting additional genes to achieve a more significant viral attenuation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15858042      PMCID: PMC1091706          DOI: 10.1128/JVI.79.10.6554-6559.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  53 in total

1.  Functional equivalency of B7-1 and B7-2 for costimulating plasmid DNA vaccine-elicited CTL responses.

Authors:  S Santra; D H Barouch; S S Jackson; M J Kuroda; J E Schmitz; M A Lifton; A H Sharpe; N L Letvin
Journal:  J Immunol       Date:  2000-12-15       Impact factor: 5.422

2.  Analysis of historical data suggests long-lasting protective effects of smallpox vaccination.

Authors:  Martin Eichner
Journal:  Am J Epidemiol       Date:  2003-10-15       Impact factor: 4.897

3.  Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV.

Authors:  I Ourmanov; C R Brown; B Moss; M Carroll; L Wyatt; L Pletneva; S Goldstein; D Venzon; V M Hirsch
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

4.  Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope.

Authors:  Laurie E Harrington; Robbert van der Most Rv; J Lindsay Whitton; Rafi Ahmed
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

5.  Vaccinia virus encodes two proteins that are structurally related to members of the plasma serine protease inhibitor superfamily.

Authors:  G J Kotwal; B Moss
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

Review 6.  Smallpox and smallpox vaccination: neurological implications.

Authors:  John Booss; Larry E Davis
Journal:  Neurology       Date:  2003-04-22       Impact factor: 9.910

7.  Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses.

Authors:  Igor M Belyakov; Patricia Earl; Amiran Dzutsev; Vladimir A Kuznetsov; Michael Lemon; Linda S Wyatt; James T Snyder; Jeffrey D Ahlers; Genoveffa Franchini; Bernard Moss; Jay A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-17       Impact factor: 11.205

Review 8.  Evaluation of 21st-century risks of smallpox vaccination and policy options.

Authors:  J Michael Lane; Joel Goldstein
Journal:  Ann Intern Med       Date:  2003-03-18       Impact factor: 25.391

9.  Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials.

Authors:  P B Gilbert; Y-L Chiu; M Allen; D N Lawrence; C Chapdu; H Israel; D Holman; M C Keefer; M Wolff; S E Frey
Journal:  Vaccine       Date:  2003-06-20       Impact factor: 3.641

10.  Developing new smallpox vaccines.

Authors:  S R Rosenthal; M Merchlinsky; C Kleppinger; K L Goldenthal
Journal:  Emerg Infect Dis       Date:  2001 Nov-Dec       Impact factor: 6.883

View more
  17 in total

1.  Treating tumors with a vaccinia virus expressing IFNβ illustrates the complex relationships between oncolytic ability and immunogenicity.

Authors:  Liang-Chuan S Wang; Rachel C Lynn; Guanjun Cheng; Edward Alexander; Veena Kapoor; Edmund K Moon; Jing Sun; Zvi G Fridlender; Stuart N Isaacs; Stephen H Thorne; Steven M Albelda
Journal:  Mol Ther       Date:  2011-10-18       Impact factor: 11.454

Review 2.  Vaccinia virus vaccines: past, present and future.

Authors:  Bertram L Jacobs; Jeffrey O Langland; Karen V Kibler; Karen L Denzler; Stacy D White; Susan A Holechek; Shukmei Wong; Trung Huynh; Carole R Baskin
Journal:  Antiviral Res       Date:  2009-06-26       Impact factor: 5.970

3.  Deletion of major nonessential genomic regions in the vaccinia virus Lister strain enhances attenuation without altering vaccine efficacy in mice.

Authors:  Julie Dimier; Audrey Ferrier-Rembert; Karine Pradeau-Aubreton; Matthias Hebben; Danièle Spehner; Anne-Laure Favier; Danielle Gratier; Daniel Garin; Jean-Marc Crance; Robert Drillien
Journal:  J Virol       Date:  2011-03-02       Impact factor: 5.103

4.  B5-deficient vaccinia virus as a vaccine vector for the expression of a foreign antigen in vaccinia immune animals.

Authors:  Kendra M Viner; Natasha Girgis; Heesun Kwak; Stuart N Isaacs
Journal:  Virology       Date:  2006-12-26       Impact factor: 3.616

5.  Antigen presentation assays to investigate uncharacterized immunoregulatory genes.

Authors:  Rachel L Roper
Journal:  Methods Mol Biol       Date:  2012

6.  Removal of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV/AIDS vaccine candidate NYVAC-C in mice.

Authors:  Carmen Elena Gómez; Beatriz Perdiguero; Jose Luis Nájera; Carlos Oscar S Sorzano; Victoria Jiménez; Rubén González-Sanz; Mariano Esteban
Journal:  J Virol       Date:  2012-03-14       Impact factor: 5.103

Review 7.  How vaccinia virus has evolved to subvert the host immune response.

Authors:  Mohammad W Bahar; Stephen C Graham; Ron A-J Chen; Samantha Cooray; Geoffrey L Smith; David I Stuart; Jonathan M Grimes
Journal:  J Struct Biol       Date:  2011-03-17       Impact factor: 2.867

8.  Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors.

Authors:  Esther D Quakkelaar; Anke Redeker; Elias K Haddad; Alexandre Harari; Stella Mayo McCaughey; Thomas Duhen; Abdelali Filali-Mouhim; Jean-Philippe Goulet; Nikki M Loof; Ferry Ossendorp; Beatriz Perdiguero; Paul Heinen; Carmen E Gomez; Karen V Kibler; David M Koelle; Rafick P Sékaly; Federica Sallusto; Antonio Lanzavecchia; Giuseppe Pantaleo; Mariano Esteban; Jim Tartaglia; Bertram L Jacobs; Cornelis J M Melief
Journal:  PLoS One       Date:  2011-02-15       Impact factor: 3.240

9.  In vitro inhibition of monkeypox virus production and spread by Interferon-β.

Authors:  Sara C Johnston; Kenny L Lin; John H Connor; Gordon Ruthel; Arthur Goff; Lisa E Hensley
Journal:  Virol J       Date:  2012-01-06       Impact factor: 4.099

10.  Human CD4+ T cell epitopes from vaccinia virus induced by vaccination or infection.

Authors:  J Mauricio Calvo-Calle; Iwona Strug; Maria-Dorothea Nastke; Stephen P Baker; Lawrence J Stern
Journal:  PLoS Pathog       Date:  2007-10-12       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.